Vincent Algalarrondo1,2, Eve Piekarski3,4, Ludivine Eliahou1,2, Dominique Le Guludec3,4, Michel S Slama1,2, François Rouzet5,6. 1. Cardiology Department, Antoine Béclère Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), UMR-S 1180, University of Paris-Sud, Clamart, France. 2. French Referral Center for Familial Amyloidotic Polyneuropathy and Other Rare Peripheral Neuropathies (CRMR-NNERF), Bicêtre, France. 3. Nuclear Medicine Department and DHU FIRE, Bichat Claude Bernard Hospital, AP-HP, University Paris VII, Paris, France. 4. Inserm UMR-S 1148, Paris, France. 5. Nuclear Medicine Department and DHU FIRE, Bichat Claude Bernard Hospital, AP-HP, University Paris VII, Paris, France. francois.rouzet@aphp.fr. 6. Inserm UMR-S 1148, Paris, France. francois.rouzet@aphp.fr.
Abstract
PURPOSE OF REVIEW: Nuclear imaging recently gained a key role in the diagnosis and prognostic assessment of transthyretin (TTR)-related cardiac amyloidosis. This review aims at summarizing the state-of-the art regarding the implementation of nuclear imaging in the management of hereditary mutated TTR-cardiac amyloidosis (mTTR-CA). RECENT FINDINGS: Although cardiac uptake of bone tracers is acknowledged as a specific marker of TTR amyloid cardiac burden, recent studies validated the implementation of bone scan in the flow chart for non-invasive diagnosis and follow-up of CA in multicenter trials. Simultaneously, cardiac denervation evidenced by MIBG scintigraphy proved to be a strong and independent prognostic marker of poor outcome in mTTR-CA. By its unique ability to assess both amyloid burden and cardiac denervation, nuclear imaging may prove useful as part of multimodality imaging tools to trigger treatment initiation and monitoring in patients with mTTR-CA.
PURPOSE OF REVIEW: Nuclear imaging recently gained a key role in the diagnosis and prognostic assessment of transthyretin (TTR)-related cardiac amyloidosis. This review aims at summarizing the state-of-the art regarding the implementation of nuclear imaging in the management of hereditary mutated TTR-cardiac amyloidosis (mTTR-CA). RECENT FINDINGS: Although cardiac uptake of bone tracers is acknowledged as a specific marker of TTR amyloid cardiac burden, recent studies validated the implementation of bone scan in the flow chart for non-invasive diagnosis and follow-up of CA in multicenter trials. Simultaneously, cardiac denervation evidenced by MIBG scintigraphy proved to be a strong and independent prognostic marker of poor outcome in mTTR-CA. By its unique ability to assess both amyloid burden and cardiac denervation, nuclear imaging may prove useful as part of multimodality imaging tools to trigger treatment initiation and monitoring in patients with mTTR-CA.
Authors: Vincent Algalarrondo; Teresa Antonini; Marie Théaudin; Béatrice Ducot; Pierre Lozeron; Denis Chemla; Anouar Benmalek; Catherine Lacroix; Daniel Azoulay; Denis Castaing; Cécile Cauquil; François Rouzet; Sylvie Dinanian; Ludivine Eliahou; Dominique Le Guludec; Didier Samuel; Michel S Slama; David Adams Journal: J Am Coll Cardiol Date: 2015-11-10 Impact factor: 24.094
Authors: Dermot Phelan; Patrick Collier; Paaladinesh Thavendiranathan; Zoran B Popović; Mazen Hanna; Juan Carlos Plana; Thomas H Marwick; James D Thomas Journal: Heart Date: 2012-08-03 Impact factor: 5.994
Authors: N Delahaye; D Le Guludec; S Dinanian; J Delforge; M S Slama; L Sarda; F Dollé; H Mzabi; D Samuel; D Adams; A Syrota; P Merlet Journal: Circulation Date: 2001-12-11 Impact factor: 29.690
Authors: Adam Castano; Muhammad Haq; David L Narotsky; Jeff Goldsmith; Richard L Weinberg; Rachelle Morgenstern; Ted Pozniakoff; Frederick L Ruberg; Edward J Miller; John L Berk; Angela Dispenzieri; Martha Grogan; Geoffrey Johnson; Sabahat Bokhari; Mathew S Maurer Journal: JAMA Cardiol Date: 2016-11-01 Impact factor: 14.676
Authors: David F Hutt; Anne-Marie Quigley; Joanne Page; Margaret L Hall; Maria Burniston; Dorothea Gopaul; Thirusha Lane; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar Journal: Eur Heart J Cardiovasc Imaging Date: 2014-06-16 Impact factor: 6.875
Authors: Mi-Ae Park; Robert F Padera; Anthony Belanger; Shipra Dubey; David H Hwang; Vikas Veeranna; Rodney H Falk; Marcelo F Di Carli; Sharmila Dorbala Journal: Circ Cardiovasc Imaging Date: 2015-08 Impact factor: 7.792
Authors: Silvia G Priori; Carina Blomström-Lundqvist; Andrea Mazzanti; Nico Blom; Martin Borggrefe; John Camm; Perry Mark Elliott; Donna Fitzsimons; Robert Hatala; Gerhard Hindricks; Paulus Kirchhof; Keld Kjeldsen; Karl-Heinz Kuck; Antonio Hernandez-Madrid; Nikolaos Nikolaou; Tone M Norekvål; Christian Spaulding; Dirk J Van Veldhuisen Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Eve Piekarski; Renata Chequer; Vincent Algalarrondo; Ludivine Eliahou; Besma Mahida; Jonathan Vigne; David Adams; Michel S Slama; Dominique Le Guludec; Francois Rouzet Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-06 Impact factor: 9.236